Hence, the reduced MGMT and ABCG2 protein expression in the GBM cells treated with TTL-EV again suggested that these dual drug combinations could be a potential therapy avenue in chemo-resistant GBM. The gene discussed is ABCG2; the disease is glioblastoma.